Development of resistance to 5-fluorouracil affects membrane viscosity and lipid composition of cancer cells.
5-fluorouracil
cancer cells
chemoresistance
fluorescence lifetime imaging microscopy FLIM
molecular rotor
plasma membrane microviscosity
time-of-flight secondary ion mass spectrometry ToF-SIMS
Journal
Methods and applications in fluorescence
ISSN: 2050-6120
Titre abrégé: Methods Appl Fluoresc
Pays: England
ID NLM: 101608648
Informations de publication
Date de publication:
25 Aug 2022
25 Aug 2022
Historique:
received:
24
02
2022
accepted:
15
08
2022
pubmed:
16
8
2022
medline:
26
8
2022
entrez:
15
8
2022
Statut:
epublish
Résumé
The investigations reported here were designed to determine whether the bulk plasma membrane is involved in mechanisms of acquired resistance of colorectal cancer cells to 5-fluorouracil (5-FU). Fluorescence lifetime imaging microscopy (FLIM) of live cultured cells stained with viscosity-sensitive probe BODIPY 2 was exploited to non-invasively assess viscosity in the course of treatment and adaptation to the drug. In parallel, lipid composition of membranes was examined with the time-of-flight secondary ion mass spectrometry (ToF-SIMS). Our results showed that a single treatment with 5-FU induced only temporal changes of viscosity in 5-FU sensitive cells immediately after adding the drug. Acquisition of chemoresistance was accompanied by persistent increase of viscosity, which was preserved upon treatment without any changes. Lipidomic analysis revealed that the resistant cells had a lower level of monounsaturated fatty acids and increased sphingomyelin or decreased phosphatidylcholine in their membranes, which partly explain increase of the viscosity. Thus, we propose that a high membrane viscosity mediates the acquisition of resistance to 5-FU.
Identifiants
pubmed: 35970177
doi: 10.1088/2050-6120/ac89cd
doi:
Substances chimiques
Phosphatidylcholines
0
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2022 IOP Publishing Ltd.